Intera Oncology Inc.

Intera Oncology Inc., a for-profit medical device manufacturer headquartered in Newton, Massachusetts, supplies hepatic artery infusion pumps and laboratory equipment to the National Cancer Institute as a prime contractor, competing in the open market without set-aside designation. The vendor operates exclusively as a prime across its federal footprint — all 45 awards are direct contracts, with no subcontract activity — and serves a single dominant customer: the National Cancer Institute accounts for 44 awards (97.8% of the portfolio) and $620 thousand in combined potential value, with a single $405 thousand purchase order from the NIH Office of Logistics and Acquisition Operations completing the remaining 2.2%.

Intera Oncology's capability portfolio centers on the Intera 3000 Hepatic Artery Infusion Pump, an FDA-approved implantable device for hepatic artery infusion therapy in cancer patients. Representative recent work includes a $404.7 thousand firm fixed-price purchase order awarded April 13, 2026 by the NCI's Surgical Oncology Program for Intera 3000 units, with a base performance period running through April 5, 2027 and option line items for additional units priced on a per-unit basis. The pump was identified as the only FDA-approved device available for the specified clinical indication, forming the basis for the sole-source award. Intera Oncology also delivers laboratory supplies and laboratory instruments — the secondary procurement categories — consistent with the vendor's categorization under NAICS 334517 (Surgical and Medical Instrument Manufacturing) and PSC Laboratory Equipment and Supplies.

Activity has remained steady but modest in scale. The vendor recorded nine awards in 2022, eleven in 2023, sixteen in 2024, eight in 2025, and one award thus far in 2026. Combined potential value across the 45-award portfolio stands at $1 million, with $798 thousand obligated (78% realization). The vendor's award values cluster in the $13 thousand to $14.4 thousand range for routine laboratory supply and equipment purchase orders, reflecting recurring replenishment cycles, with the $404.7 thousand April 2026 order representing a material outlier driven by a multi-unit pump procurement. Intera Oncology operates through direct purchase orders issued by NCI and does not participate in broader federal contract vehicles such as GWACs, BPAs, or IDIQs. The absence of subcontract activity and the single-customer concentration indicate a vendor relationship structure built entirely on direct supply to one federal research institution rather than indirect access through prime contractors or participation in shared vehicle infrastructure.